首页> 美国政府科技报告 >Evaluating Interstrand Crosslink (ICL) Repair in Triple-Negative Breast Cancers to Guide Chemotherapy.
【24h】

Evaluating Interstrand Crosslink (ICL) Repair in Triple-Negative Breast Cancers to Guide Chemotherapy.

机译:评估三阴性乳腺癌的Interstrand交联(ICL)修复指导化疗。

获取原文

摘要

The main goals of this proposal are: 1) to develop and optimize a rapid method to assess the ability of breast tumor cell lines to repair specifically DNA interstrand crosslinks (ICLs). 2) to apply this technology to a set of human breast cancer cell lines. In addition, we propose to compare ICLs repair with surrogate markers for ICL repair. The predicted outcome of these studies is to identify a subset of human breast tumor cell lines that are cisplatinsensitive and to correlate this sensitivity with their ability to repair ICLs. We hypothesized that breast cancer cell lines with defects in ICL repair will fall into the basal-like/triple-negative breast cancer category of tumor cell lines and correlate with an increased sensitivity to cisplatin.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号